Cargando…
Secondary prophylaxis in rheumatic fever: is it time to change?
Autores principales: | Taddio, Andrea, Pirrone, A, Pastore, Serena, Lepore, Loredana, Di Battista, Caterina, Simonini, Gabriele, Breda, Luciana, Cimaz, Rolando |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707598/ http://dx.doi.org/10.1186/1824-7288-41-S2-A71 |
Ejemplares similares
-
Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis
por: Simonini, Gabriele, et al.
Publicado: (2013) -
Lysosomal storage disorders for the pediatric rheumatologist: the example of mucopolysaccharydoses
por: Cimaz, Rolando, et al.
Publicado: (2015) -
State of rheumatic fever in Algeria. Viewpoint of a cardiac surgeon.
por: Bouzid, Abdelmalek, et al.
Publicado: (2015) -
Adherence to Secondary Prophylaxis Among Patients with Acute
Rheumatic Fever and Rheumatic Heart Disease
por: Woods, John A., et al.
Publicado: (2019) -
Adherence to Secondary Prophylaxis for Acute Rheumatic Fever and Rheumatic Heart Disease: A Systematic Review
por: Kevat, Priya M., et al.
Publicado: (2017)